A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China

Gu, Zhenyang; Dong, Yi; Fu, Xiaorui; Li, Nai-Nong; Liu, Yao; Wu, Xue-Ru; Wang, Yini; Li, Yu-Hang; Ren, Hanyun; Zhang, Mingzhi; Li, Xiaofan; Wang, Maihong; Yamei, Wu; Liu, Dai‐Hong; Wang, Zhao; Hu, Liangding; Huang, Wenrong

doi:10.1097/cm9.0000000000001575

Cited by 4 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seventeen patients received auto‐HSCT, and 20 patients received allo‐HSCT. The research show that ASCT seemed to be associated with better survival for patients in good condition (3‐year OS: 85% vs. 40%, p = .003) 26 . A French study included 65 advanced ENKTL patients, the OS and PFS of ASCT and allo‐HSCT were similar.…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Up‐front autologous hematopoietic stem cell transplantation after first complete remission improved prognosis of advanced extra‐nodal NKT cell lymphoma: A multicenter real‐world study in China

Gao

Lin

et al. 2023

European J of Haematology

View full text Add to dashboard Cite

Objectives The advanced extra‐nodal NK/T‐cell lymphoma (ENKTL) is highly aggressive and lacks effective treatment with a poor prognosis. This study aimed to investigate the effectiveness and safety of autologous hematopoietic stem cell transplantation (ASCT) in CR1. Methods Forty of 121 patients with advanced ENKTL from four Chinese hospitals between January 2006 to December 2021 who achieved first complete remission (CR1) and received at least 4 cycles chemotherapy, were enrolled for analysis. Twenty patients received ASCT as up‐front consolidation therapy (Group A), and 20 patients only received chemotherapy (Group B). Clinical features, treatment and follow‐up information were collected. Results With a median follow‐up of 27 months (range, 4–188 months), the 2‐year overall survival (OS) in Group A, 61% (95% CI 37%–85%), was better than that in Group B, 26% (95% CI 2%–50%), p = .018. The 2‐year progression‐free survival (PFS) was 56% (95% CI 32%–80%) in Group A, 26% (95% CI 2%–50%) in Group B, p = .026. III–IV grade hematological toxicity was the most common adverse event. No treatment‐related deaths were observed in both groups. Conclusion Up‐front ASCT could improve survival of advanced ENKTL patients in first complete remission, but need be confirmed by a prospective clinical trial.

show abstract

Section: Discussionmentioning

confidence: 94%

“…The research show that ASCT seemed to be associated with better survival for patients in good condition (3-year OS: 85% vs. 40%, p = .003). 26 A French study included 65 advanced ENKTL patients, the OS and PFS of ASCT and allo-HSCT were similar. The 4 years OS were 52% versus 53%, and the PFS were 34% versus 26%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Up‐front autologous hematopoietic stem cell transplantation after first complete remission improved prognosis of advanced extra‐nodal NKT cell lymphoma: A multicenter real‐world study in China

Gao

Lin

et al. 2023

European J of Haematology

View full text Add to dashboard Cite

show abstract

Mitoxantrone‐Based Novel Conditioning Regimen Leads to Great Survival Benefit in Peripheral T‐Cell Lymphoma Compared to BEAM Regimen

Zuo,

Qian,

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

BackgroundPeripheral T‐cell lymphomas (PTCL) frequently result in relapsed or refractory diseases. Upfront autologous hematopoietic stem cell transplantation (ASCT) using the BEAM (carmustine, etoposide, cytarabine, and melphalan) regimen is recommended. However, relapses are common in PTCL, highlighting a critical need for improved survival outcomes in these patients.ObjectiveAnthracycline drugs are essential in treating PTCL. We compared the efficacy and tolerability of a high‐dose mitoxantrone‐based conditioning regimen [mitoxantrone, cyclophosphamide, and etoposide (MCE)] to the BEAM regimen in upfront ASCT for newly diagnosed PTCL patients who achieved complete or partial remission after induction therapy.Study DesignA retrospective study was conducted to analyze the treatment response, progression‐free survival (PFS), overall survival (OS), hematologic engraftment time, and adverse events of 64 patients between two regimens, who achieved complete or partial remission after induction chemotherapy. Twenty‐eight patients received the MCE regimen, while 36 patients were treated with the BEAM regimen.ResultsThere were no significant differences in clinical characteristics or the incidence of adverse events between the two groups. However, the median OS significantly favored the MCE group at 102.4 (95% CI, 87.0–117.8) months compared to 62.6 (95% CI, 50.8–74.5) months in the BEAM group (p = 0.023). Similarly, the median PFS was longer in the MCE group at 87.8 (95% CI, 65.8–109.8) months versus 42.5 (95% CI, 30.0–55.0) months in the BEAM group (p = 0.031).ConclusionASCT with the mitoxantrone‐based conditioning regimen is tolerable and appears to significantly improve the prognosis of PTCL patients, offering a promising alternative to the current standard of care.

show abstract

Ten-year epidemiology and risk factors of cytomegalovirus infection in hematopoietic stem cell transplantation patients in Taiwan

Huang,

Hsiao,

Guan

et al. 2024

Journal of Microbiology, Immunology and Infection

View full text Add to dashboard Cite

A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China

Abstract: Supplemental Digital Content is available in the text

Cited by 4 publications

References 28 publications

Up‐front autologous hematopoietic stem cell transplantation after first complete remission improved prognosis of advanced extra‐nodal NKT cell lymphoma: A multicenter real‐world study in China

Up‐front autologous hematopoietic stem cell transplantation after first complete remission improved prognosis of advanced extra‐nodal NKT cell lymphoma: A multicenter real‐world study in China

Mitoxantrone‐Based Novel Conditioning Regimen Leads to Great Survival Benefit in Peripheral T‐Cell Lymphoma Compared to BEAM Regimen

Ten-year epidemiology and risk factors of cytomegalovirus infection in hematopoietic stem cell transplantation patients in Taiwan

Contact Info

Product

Resources

About